Bibliography
- Kupferberg HJ : Quantitative estimation of diphenylhydantoin, primidone and phenobarbital in plasma by gas–liquid chromatography.Clin. Chim. Acta29, 282–288 (1970).
- Pippenger CE , GillenHW: Gas chromatographic analysis for anticonvulsant drugs in biologic fluids.Clin. Chem.15, 582–590 (1969).
- Chung A , KimSY, ChengLT, CastroA: Phenobarbital specific antisera and radioimmunoassay.Experientia29, 820–821 (1973).
- Tigelaar RE , RapportRL 2nd, Inman JK, Kupferberg HJ: A radioimmunoassay for diphenylhydantoin. Clin. Chim. Acta.43, 231–241 (1973).
- Sun L , WalwickER: Primidone analyses: correlation of gas–chromatographic assay with enzyme immunoassay.Clin. Chem.22, 901–902 (1976).
- Bardin S , OttingerJC, BreauAP, O’SheaTJ: Determination of free levels of phenytoin in human plasma by liquid chromatography/tandem mass spectrometry.J. Pharm. Biomed. Anal.23, 573–579 (2000).
- Ifa DR , FalciM, MoraesME, BezerraFA, MoraesMO, de Nucci G: Gabapentin quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study. J. Mass Spectrom.36, 188–194 (2001).
- Di S alle E, Pacifici GM, Morselli PL: Studies on plasma protein binding of carbamazepine. Pharmacol. Res. Commun.6, 193–202 (1974).
- Lightfoot RW , Jr, Christian CL: Serum protein binding of thyroxine and diphenylhydantoin. J. Clin. Endocrinol. Metab.26, 305–308 (1966).
- Loscher W : Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse.J. Pharmacol. Exp. Ther.204, 255–261 (1978).
- Luer MS , RhoneyDH: Tiagabine: a novel antiepileptic drug.Ann. Pharmacother.32, 1173–1180 (1998).
- Brodie MJ , DichterMA: Established antiepileptic drugs.Seizure6, 159–174 (1997).
- Johannessen SI , BattinoD, BerryDJ et al.: Therapeutic drug monitoring of the newer antiepileptic drugs.Ther. Drug Monit.25, 347–363 (2003).
- Kupferberg HJ : Applying TDM to Antiepileptic Drugs. Clarke W (Chair), AACC Personalized Medicine conference, September 29–30, 2005, Crystal City, VA, USA (2005).
- Spina E , PerugiG: Antiepileptic drugs: indications other than epilepsy.Epileptic Disord.6, 57–75 (2004).
- Rogawski MA , LoscherW: The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions.Nature Med.10, 685–692 (2004).
- Bowden CL , CalabreseJR, SachsG et al.: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psychiatry60, 392–400 (2003).
- Hirschfeld RM , KasperS: A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder.Int. J. Neuropsychopharmacol.7, 507–522 (2004).
- Bowden CL , BruggerAM, SwannAC et al.: Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA271, 918–924 (1994).
- Wiffen P , CollinsS, McQuayH, CarrollD, JadadA, MooreA: Anticonvulsant drugs for acute and chronic pain.Cochrane Database Syst. Rev., CD001133 (2005).
- Schneider JP : Chronic pain management in older adults: with coxibs under fire, what now?Geriatrics60, 26–28, 30–31 (2005).
- Gilron I , BaileyJM, TuD, HoldenRR, WeaverDF, HouldenRL: Morphine, gabapentin, or their combination for neuropathic pain.N. Engl. J. Med.352, 1324–1334 (2005).
- D’Amico D , GrazziL, UsaiS, MoschianoF, BussoneG: Topiramate in migraine prophylaxis.Neurol. Sci.26(Suppl. 2), 130–133 (2005).
- Tomson T , TybringG, BertilssonL, Ekbom K, Rane A: Carbamazepine therapy in trigeminal neuralgia: clinical effects in relation to plasma concentration. Arch. Neurol.37, 699–703 (1980).
- French JA , KannerAM, BautistaJ et al.: Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology62, 1261–1273 (2004).
- French JA , KannerAM, BautistaJ et al.: Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology62, 1252–1260 (2004).
- Rasmussen PV , JensenTS, SindrupSH, BachFW: TDM-based imipramine treatment in neuropathic pain.Ther. Drug Monit.26, 352–360 (2004).
- Armijo JA , PenaMA, AdinJ, Vega-GilN: Association between patient age and gabapentin serum concentration-to-dose ratio: a preliminary multivariate analysis.Ther. Drug Monit.26, 633–637 (2004).
- Guzey C , SpigsetO: Genotyping as a tool to predict adverse drug reactions.Curr. Top. Med. Chem.4, 1411–1421 (2004).
- Pirmohamed M , ParkBK: Cytochrome P450 enzyme polymorphisms and adverse drug reactions.Toxicology192, 23–32 (2003).
- Meyer UA : Pharmacogenetics and adverse drug reactions.Lancet356, 1667–1671 (2000).
- Jannetto PJ , WongSH, GockSB, Laleli-SahinE, SchurBC, JentzenJM: Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases.J. Anal. Toxicol.26, 438–447 (2002).
- Koski A , SistonenJ, OjanperaI, GergovM, VuoriE, SajantilaA: CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies.Forensic Sci. Int. (2005).
- Sallee FR , DeVaneCL, FerrellRE: Fluoxetine-related death in a child with cytochrome P450 2D6 genetic deficiency.J. Child Adolesc. Psychopharmacol.10, 27–34 (2000).
- Citerio G , NobiliA, AiroldiL, PastorelliR, PatrunoA: Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reaction.Neurology60, 1395–1396 (2003).
- Hardman JG , LimbirdLE, GilmanAG (Eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics. Tenth edition, McGraw-Hill, CA, USA (2001).
- Rendic S , Di Carlo FJ: Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev.29, 413–580 (1997).
- Kirchheiner J , BrockmollerJ: Clinical consequences of cytochrome P450 2C9 polymorphisms.Clin. Pharmacol. Ther.77, 1–16 (2005).
- Zanger UM , RaimundoS, EichelbaumM: Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.Naunyn Schmiedebergs Arch. Pharmacol.369, 23–37 (2004).
- Klotz U , SchwabM, TreiberG: CYP2C19 polymorphism and proton pump inhibitors.Basic Clin. Pharmacol. Toxicol.95, 2–8 (2004).
- Bradford LD : CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.Pharmacogenomics3, 229–243 (2002).
- Ingelman-Sundberg M : Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.Trends Pharmacol. Sci.25, 193–200 (2004).
- Mizutani T : PM frequencies of major CYPs in Asians and Caucasians.Drug Metab. Rev.35, 99–106 (2003).
- Solus JF , AriettaBJ, HarrisJR et al.: Genetic variation in eleven Phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics5, 895–931 (2004).
- van der Weide J , SteijnsLS: Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology.Ann. Clin. Biochem.36(Pt 6), 722–729 (1999).
- Ikenaga Y , FukudaT, FukudaK et al.: The frequency of candidate alleles for CYP2D6 genotyping in the Japanese population with an additional respect to the -1584C to G substitution.Drug Metab. Pharmacokinet.20(2), 113–116 (2005).
- McMillin GA , LinderMW, BukaveckasBL: Pharmacogenetics. In:Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, Fourth edition. Burtis CA, Ashwood ER, Bruns DE (Eds). Elsevier Saunders, St Louis, MO, USA (2005).
- Hung CC , LinCJ, ChenCC, ChangCJ, LiouHH: Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.Ther. Drug Monit.26, 534–540 (2004).
- Kirchheiner J , NickchenK, BauerM et al.: Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.Mol. Psychiatry9, 442–473 (2004).
- Steimer W , ZopfK, von Amelunxen S et al.: Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin. Chem.50, 1623–1633 (2004).
- Armstrong SC , CozzaKL: Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II.Psychosomatics44, 515–520 (2003).
- Flores CM , MogilJS: The pharmacogenetics of analgesia: toward a genetically-based approach to pain management.Pharmacogenomics2, 177–194 (2001).
- Gasche Y , DaaliY, FathiM et al.: Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med.351, 2827–2831 (2004).
- Swanson JR , JonesGR, KrasseltW, DenmarkLN, RattiF: Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms.J. Forensic Sci.42, 335–339 (1997).
- Steimer W , ZopfK, von Amelunxen S et al.: Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin. Chem.51, 376–385 (2005).
- Giancarlo GM , VenkatakrishnanK, Granda BW, von Moltke LL, Greenblatt DJ: Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur. J. Clin. Pharmacol.57, 31–36 (2001).
- Mamiya K , IeiriI, ShimamotoJ et al.: The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia39, 1317–1323 (1998).
- Lindhout D : Pharmacogenetics and drug interactions: role in antiepileptic-drug-induced teratogenesis.Neurology42, 43–47 (1992).
- Nakajima Y , SaitoY, ShisekiK et al.: Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. Eur. J. Clin. Pharmacol.61, 25–34 (2005).
- Tate SK , DepondtC, SisodiyaSM et al.: Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc. Natl Acad. Sci. USA102, 5507–5512 (2005).
- Patsalos PN : Antiepileptic drug pharmacogenetics.Ther. Drug Monit.22, 127–130 (2000).
- Goldstein DB , TateSK, SisodiyaSM: Pharmacogenetics goes genomic.Nature Rev. Genet.4, 937–947 (2003).
- Evans WE , McLeodHL: Pharmacogenomics – drug disposition, drug targets, and side effects.N. Engl. J. Med.348, 538–549 (2003).
- Kerb R , AynaciogluAS, BrockmollerJ et al.: The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J.1, 204–210 (2001).
- Kowalski R , PostD, SchneiderMC et al.: Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin. Transplant17, 77–88 (2003).
- Drynda S , RingelB, KekowM et al.: Proteome analysis reveals disease-associated marker proteins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti-TNFα therapy. Pathol. Res. Pract.200, 165–171 (2004).
- Fortman CS , WitteDL: Serum 5′-nucleotidase in patients receiving anti-epileptic drugs.Am. J. Clin. Pathol.84, 197–201 (1985).
- Csathy L , OlahAV, ClemensB, GyorgyI, VargaJ: Urinary N-acetyl-β-d-glucosaminidase in epileptic children treated with antiepileptic drugs.Arch. Dis. Child83, 420–422 (2000).
- Glauser TA : Idiosyncratic reactions: new methods of identifying high-risk patients.Epilepsia41(Suppl. 8), S16–S29 (2000).
Website
- Sim SC: CYP Alleles. www.imm.ki.se/CYPalleles